Opinionated Science Episode 10: COVID-19 Vaccines: Three Leading Candidates, Assessed

Podcast

Published: July 31, 2020

Opinionated Science Episode 10: COVID-19 Vaccines: Three Leading Candidates, Assessed content piece image

Opinionated Science is Technology Networks’ homemade podcast, where our team of scientists-turned-journalists cut out the chewy jargon and serve up slices of the most fascinating stories from the world of science. Expect a new Opinionated Science every other Friday.

In this episode, the TN team discusses three promising vaccine candidates being developed for COVID-19. We take a deep dive into the data from these vaccine trials to try and work out what successes can be celebrated and what unanswered questions still remain.

Read more from this podcast:

V accine 1: Moderna's mRNA-1273

Vaccine 2: Oxford University's ChAdOx1

Vaccine 3: CanSino Biologics' Adenovirus Type-5

Antigen vs Antibody – What Are the Differences?

A Vaccine 101

Exploring the Drug Development Process

Moderna's COVID-19 Vaccine Shows Positive Interim Results in Phase I Trial

Listen to more Technology Networks podcasts here.

Subscribe to Opinionated Science at your favorite podcast platform:

Listen here on Spotify.

Listen here on Apple Podcasts.

Meet the Authors

Ruairi J Mackenzie

RJ is a freelance science writer based in Glasgow. He covers biological and biomedical science, with a focus on the complexities and curiosities of the brain and emerging AI technologies. RJ was a science writer at Technology Networks for six years. RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge.

Molly Campbell

Senior Science Writer

Molly Campbell is a senior science writer at Technology Networks. She holds a first-class honors degree in neuroscience. In 2021 Molly was shortlisted for the Women in Journalism Georgina Henry Award.

Karen Steward, PhD

Senior Scientific Specialist

Karen Steward holds a PhD in molecular microbiology and evolutionary genetics from the University of Cambridge. She moved into science writing in 2017 after over a decade as a research scientist.